South
African doctors have found a high prevalence of multi-drug resistant
tuberculosis among children receiving care in a Johannesburg
hospital, highlighting the need to screen for drug resistance and
test for HIV in children with TB symptoms.
Among
a cohort of children with culture-confirmed tuberculosis in
Johannesburg, South Africa, a setting with high rates of HIV
co-infection, 8.8% (95% CI: 4.8-14.6%) had multi-drug resistant
tuberculosis (MDR-TB) and 14.2% (95% CI: 9.0-20.9%) were isoniazid
resistant according to Lee Fairlie and colleagues in a retrospective
cross-sectional study published in the January 26 edition of BMC
Infectious Diseases.
Only
four of the children with MDR-TB had contact with an adult with TB,
none of whom had MDR-TB suggesting that MDR-TB occurred within the
community as well as the household, the authors note. They add this
probably indicates a significant number of undiagnosed drug-resistant
TB among adult contacts of these children.
The
authors add that in spite of high prevalence of HIV co-infection no
association between HIV and MDR-TB was found.
Sub-Saharan
Africa has a high burden of both HIV and TB. The majority of the
estimated 2.5 million children with HIV live in sub-Saharan Africa,
of which 10% are in South Africa. In 2007 of the 2.9 million new
cases of TB in sub-Saharan Africa, 10% were in children; close to 40%
of all cases were co-infected with HIV.
Global
prevalence of MDR-TB in adults, meaning resistance to at least
isoniazid and rifampicin was estimated to be 4.6% in 2006, the
authors note. Data on the prevalence of drug resistance in children
with TB in Africa are limited and estimated at 0.6-6.7%.
Children
with TB, the authors note, usually represent cases of recently
acquired infection so are an important measure of on-going adult
disease and “the drug-susceptibility patterns and circulating
strain diversity of TB in a community.”
The
authors undertook an analysis of the prevalence of MDR-TB in children
under 14 years of age with culture-confirmed TB diagnosed between
January 1 and December 31, 2008 at Chris Hani-Baragwanath Hospital
(CHBH) and Rahima Moosa Mother and Child Hospital (RMMCH) in
Johannesburg, South Africa. They reviewed laboratory data including
clinical and radiological outcomes at six and 12 months
post-diagnosis.
1317
children were treated for TB in 2008 at CHBH and RMMCH. Of the 204
children with culture-confirmed TB, 148 (72.5%) underwent drug
susceptibility testing (DST).
Among
whom, the authors note, the high MDR-TB prevalence rate of 8.8% was
higher than in previous African paediatric studies (2.3-6.7%). These
results suggest a high prevalence of MDR-TB within this setting where
contact tracing is poorly performed, they add.
16%
had drug resistant TB. Of the 14% of children resistant to isoniazid
75% were HIV-infected. The high rates of isoniazid resistance could
affect the recently recommended South African TB guidelines raising
questions about the effectiveness of isoniazid preventive therapy
(IPT) in this community, note the authors. It may partly explain why
primary isoniazid prophylaxis is not effective in improving TB-free
survival of HIV infected children in this setting, they add.
South
African TB guidelines do not recommend routine DST in adults or
children. However, the authors note that planning is in process to
improve routine testing of all smear-positive adults and paediatric
specimens using a line probe assay and so report drug sensitivity
patterns more rapidly.
Of
the 13 children with MDR-TB, ten (76.9%) were treated of which four
(30.8%) died at a median of 2.8 months (0.1-4.0 months) after
diagnosis. Three of the children were HIV-infected and on
antiretrovirals and were started on MDR-TB treatment with no
significant delay compared to those who lived. Previous reported
paediatric studies in the Western Cape and in Lima, Peru had
significantly lower mortality rates, 10% over a four year period with
50% HIV co-infected and 3.5%, respectively.
The
authors note that all the children died in hospital highlighting the
problems of infection control. In many general hospitals in South
Africa appropriate isolation facilities are lacking. Even with
efficient and swift diagnosis of MDR-TB there will be, nonetheless,
an increased risk of transmission. The authors stress the urgency for
infection control needs to be addressed in areas of increased MDR-TB
rates and high HIV prevalence.
Limitations
according to the authors include a possible overestimation of MDR-TB
prevalence since those who attend referral hospitals may be at
increased risk compared to those treated in primary care facilities.
DST at the clinician’s discretion undertaken in 72.5% of children
with culture-confirmed TB may have introduced bias.
The
authors conclude the high prevalence of drug-resistant tuberculosis
“likely represents a large burden of undiagnosed drug-resistant TB
in household and community adult contacts of these children.”
“Routine HIV [testing] and DST are warranted to optimise the
management of childhood tuberculosis in settings such as ours.”